Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 1
1966 3
1967 1
1968 2
1970 1
1971 3
1972 3
1973 1
1974 4
1975 3
1976 4
1977 4
1978 2
1979 3
1980 1
1981 6
1982 4
1983 2
1984 2
1985 4
1986 5
1987 5
1988 4
1989 6
1990 5
1991 9
1992 9
1993 10
1994 6
1995 13
1996 6
1997 13
1998 7
1999 13
2000 19
2001 15
2002 18
2003 17
2004 25
2005 30
2006 28
2007 25
2008 16
2009 19
2010 17
2011 29
2012 25
2013 27
2014 25
2015 27
2016 36
2017 43
2018 59
2019 63
2020 81
2021 59
2022 39
2023 46
2024 55
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

887 results

Results by year

Filters applied: . Clear all
Page 1
IGF2 Mutations.
Masunaga Y, Inoue T, Yamoto K, Fujisawa Y, Sato Y, Kawashima-Sonoyama Y, Morisada N, Iijima K, Ohata Y, Namba N, Suzumura H, Kuribayashi R, Yamaguchi Y, Yoshihashi H, Fukami M, Saitsu H, Kagami M, Ogata T. Masunaga Y, et al. Among authors: fujisawa y. J Clin Endocrinol Metab. 2020 Jan 1;105(1):dgz034. doi: 10.1210/clinem/dgz034. J Clin Endocrinol Metab. 2020. PMID: 31544945 Review.
Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren's syndrome.
Flores-Chávez A, Brito-Zerón P, Ng WF, Szántó A, Rasmussen A, Priori R, Baldini C, Armagan B, Özkiziltaş B, Praprotnik S, Suzuki Y, Quartuccio L, Hernández-Molina G, Inanc N, Bartoloni E, Rischmueller M, Reis-de Oliveira F, Fernandes Moça Trevisani V, Jurcut C, Nordmark G, Carubbi F, Hofauer B, Valim V, Pasoto SG, Retamozo S, Atzeni F, Fonseca-Aizpuru E, López-Dupla M, Giacomelli R, Nakamura H, Akasbi M, Thompson K, Fanny Horváth I, Farris AD, Simoncelli E, Bombardieri S, Kilic L, Tufan A, Perdan Pirkmajer K, Fujisawa Y, De Vita S, Abacar K, Ramos-Casals M; Sjögren Big Data Consortium. Flores-Chávez A, et al. Among authors: fujisawa y. Clin Exp Rheumatol. 2023 Dec;41(12):2437-2447. doi: 10.55563/clinexprheumatol/pmbay6. Epub 2023 Nov 27. Clin Exp Rheumatol. 2023. PMID: 38019164 Free article.
Anatomic Subtype Differences in Extramammary Paget Disease: A Meta-Analysis.
Kibbi N, Owen JL, Worley B, Wang JX, Harikumar V, Aasi SZ, Chandra S, Choi JN, Fujisawa Y, Iavazzo C, Kim JYS, Lawrence N, Leitao MM Jr, MacLean AB, Ross JS, Rossi AM, Servaes S, Solomon MJ, Alam M. Kibbi N, et al. Among authors: fujisawa y. JAMA Dermatol. 2024 Apr 1;160(4):417-424. doi: 10.1001/jamadermatol.2024.0001. JAMA Dermatol. 2024. PMID: 38446447
Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility.
Pinto EM, Fridman C, Figueiredo BC, Salvador H, Teixeira MR, Pinto C, Pinheiro M, Kratz CP, Lavarino C, Legal EAMF, Le A, Kelly G, Koeppe E, Stoffel EM, Breen K, Hahner S, Heinze B, Techavichit P, Krause A, Ogata T, Fujisawa Y, Walsh MF, Rana HQ, Maxwell KN, Garber JE, Rodriguez-Galindo C, Ribeiro RC, Zambetti GP. Pinto EM, et al. Among authors: fujisawa y. HGG Adv. 2024 Jan 11;5(1):100244. doi: 10.1016/j.xhgg.2023.100244. Epub 2023 Oct 4. HGG Adv. 2024. PMID: 37794678 Free PMC article.
Clec10a regulates mite-induced dermatitis.
Kanemaru K, Noguchi E, Tahara-Hanaoka S, Mizuno S, Tateno H, Denda-Nagai K, Irimura T, Matsuda H, Sugiyama F, Takahashi S, Shibuya K, Shibuya A, Fujisawa Y, Nakamura Y. Kanemaru K, et al. Among authors: fujisawa y. Sci Immunol. 2019 Dec 6;4(42):eaax6908. doi: 10.1126/sciimmunol.aax6908. Sci Immunol. 2019. PMID: 31811054
A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
Fujimura T, Yoshino K, Kato H, Fukushima S, Ishizuki S, Otsuka A, Matsushita S, Amagai R, Muto Y, Yamazaki E, Kambayashi Y, Yahata T, Miyata T, Fujisawa Y, Asano Y. Fujimura T, et al. Among authors: fujisawa y. Br J Dermatol. 2024 Oct 17;191(5):691-697. doi: 10.1093/bjd/ljae231. Br J Dermatol. 2024. PMID: 38833158 Clinical Trial.
Trehalose Prevents IL-4/IL-13-Induced Skin Barrier Impairment by Suppressing IL-33 Expression and Increasing NRF2 Activation in Human Keratinocytes In Vitro.
Dai X, Mizukami Y, Watanabe K, Tsuda T, Shidahara M, Yoshida S, Yatsuzuka K, Shiraishi K, Mori H, Murakami M, Kawakami R, Imamura T, Fujisawa Y, Muto J. Dai X, et al. Among authors: fujisawa y. J Invest Dermatol. 2024 Oct 9:S0022-202X(24)02175-4. doi: 10.1016/j.jid.2024.08.038. Online ahead of print. J Invest Dermatol. 2024. PMID: 39384017
887 results